Study

EORTC-26101

Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma – previously: Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma

Study documentation Back to result

Trial Status

All trial activities ended

Dates

Date of activation: 07-Oct-2011
Date Step1 close: 07-Jan-2015

Data management at EORTC

Yes

Design

Phase 3
Randomized open label

Targeted Sample size

EORTC Groups: 592 - All Groups: 592

Protocol summary

http://clinicaltrials.gov/study/NCT01290939

NCT number

NCT01290939

EudraCT

2010-023218-30

Study

EORTC-26101

Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma – previously: Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma

Study documentation Back to result

Research Projects

RP-1626-QLG

Predictors of quality of life ratings from patients with primary brain tumors: the role of self-awareness and cognitive functioning